Navigation Links
Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
Date:7/28/2009

ealing agents or devices in use that require repeated administrations over a long term (weeks to months). Based on recently announced advancements, Excellarate is also expected to be re-formulated as an easy-to-use single syringe, which would be pre-mixed and ready to be applied to patients' wounds. The reformulation will allow Excellarate to be maintained in a physician's office using a standard refrigerator (at a temperature of about 4 degrees C) and is expected to have a shelf life of 12-18 months.

About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for tissue repair and cardiovascular indications. In May 2009, Cardium announced completion of the enrollment for the Matrix Phase 2b clinical study to evaluate the Excellarate product candidate as a treatment for patients with non-healing diabetic ulcers. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that the MATRIX study or other human clinical trials can be conducted and completed in an efficient and successful manner, that product formulat
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cardium Regains Listing Compliance with NYSE Amex
2. Cardiums InnerCool Therapies Business to Be Acquired By Royal Philips Electronics
3. Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Development Program
4. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
5. Cardium Completes $3.5 Million Credit Facility
6. Cardium Announces Retirement of Director
7. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
8. Cardiums InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
9. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
10. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
11. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Victoria, Australia (PRWEB) September 02, 2014 ... provide a cure for chronic tinnitus are seeking support ... run on the Indiegogo platform ( http://igg.me/at/tinaway ), was ... to be a therapeutic ‘mHealth’ app and is based ... brainchild of a team of biomedical and software engineers, ...
(Date:9/1/2014)... NewYork (PRWEB) September 01, 2014 ... Biotech and Diagnostics report provides comprehensive understanding and ... agreements entered into by the worlds leading life ... understand and analysis of how and why companies ... of a prospective partner’s negotiated deals terms provides ...
(Date:8/31/2014)... August 31, 2014 2014 ... is a professional and in-depth research report ... basic Polyacrylamide information, including Polyacrylamide definition, classification, ... as industry overview. This research covers the ... well as global industry analysis covering macroeconomic ...
(Date:8/29/2014)... SAN DIEGO, Aug. 29, 2014  Pfenex Inc. ... in the development of high-value and difficult to ... business update and reported financial results for the ... "With the successful completion of our initial public ... advance our biosimilar product candidates, derived from our ...
Breaking Biology Technology:tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... ... the availability of two new atomic force microscope (AFM) probes types with carbon nanotube ... CNT probes offer quantum improvements for AFM imaging, substantially improving results, reducing overall cost ... ...
... FRANCISCO, Calif., June 16 Sunesis Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of new oncology therapeutics for the treatment of ... Executive Officer of Sunesis, will be presenting at the Jefferies ... New York on June 17, 2009. , , The ...
... 16 Three Rivers Pharmaceuticals announced today positive results ... Efficacy of Combined Therapy (DIRECT) clinical trial authored by ... , and colleagues at 44 centers in the United ... (SVR), was achieved demonstrating that INFERGEN provides a second ...
Cached Biology Technology:Carbon Design Innovations, Inc. Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy, CNT-Probes Deliver New Level of AFM Imaging Performance 2Carbon Design Innovations, Inc. Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy, CNT-Probes Deliver New Level of AFM Imaging Performance 3Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures 2Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures 3Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures 4
(Date:9/2/2014)... to prevent Type 2 diabetes, don,t get your hopes up. ... The FASEB Journal , suggests that you don,t ... study compared genetically identical twins-one heavier and one leaner-and found ... those related to Type 2 diabetes, were found in both ... the onset of this type of diabetes is largely influenced ...
(Date:9/2/2014)... your integrity? Tell the truth; everyone has a tipping point. ... we,ll lie if the benefit is great enough. Now, scientists ... make that decision. , The result was published online ... "We prefer to be honest, even if lying is beneficial," ... associate at the Virginia Tech Carilion Research Institute , ...
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
Breaking Biology News(10 mins):What you eat and not just the number of calories, is a significant factor in diabetes risk 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Exceptionally well preserved insect fossils from the Rhône Valley 2
... Calif. UC Riverside,s Alexander Raikhel , a professor ... National Academy of Sciences (NAS) for his excellence in ... is one of the highest honors given to a scientist ... inducted into the academy next April during its 147th annual ...
... the 61st Annual Meeting of the Rocky Mountain Section ... May 2009 in Orem, Utah. Utah Valley University ... building on the UVU campus. Brigham Young University is ... industry scientists, and graduate and undergraduate students, will highlight ...
... million in U.S. dollars have been awarded to ... studies related to asthma and other immune system ... extramural grants were awarded by the Biomedical Research ... and Research), the government agency driving Singapore,s transformation ...
Cached Biology News:UC Riverside professor receives top scientific honor 2UC Riverside professor receives top scientific honor 3Geoscientists meet to discuss Rocky Mountain geology 2Alzheimer's, asthma, cancer, malaria and TB focus of new Singapore grants 2Alzheimer's, asthma, cancer, malaria and TB focus of new Singapore grants 3Alzheimer's, asthma, cancer, malaria and TB focus of new Singapore grants 4
Anti-LC3 Polyclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Rabbit polyclonal to Xanthine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Xanthine Oxidase (from Bovine Buttermilk) Entrez Gene ID: 7498 Swiss Protein ID: P47989...
... Disrupts biological cells for DNA isolation. ... well plates (includes 96 well plate ... lysis across the entire plate length ... Can be used for soil, ...
Biology Products: